A Phase 1, First-in-human Study of VX-668

Clinical trial NCT05727800 · COMPLETED

Trial details

NCT number: NCT05727800
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Alpha-1 Antitrypsin Deficiency

Start date: 2023-02-08
Primary completion: 2023-09-12
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.